AstraZeneca raises profit outlook on strong medicines demand
Expects 2024 sales and profit to grow by a mid teens percentage
Q2 sales of $12.94 billion beat forecast, core EPS $1.98 in line
Shares fell as much as 4%
Updates shares in paragraph 4
By Pushkala Aripaka and Maggie Fick
July 25 (Reuters) -Anglo-Swedish drugmaker AstraZeneca AZN.L raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines.
Sales in AstraZeneca's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while its rare disease and heart and kidney disease divisions also each raked in double-digit growth.
Second-quarter profit though was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said.
The shares slipped by as much as 4%. They were down 2.4% at 1000GMT after gains of about 14% so far this year. But on Thursday they wereone of the worst performers in the European pharma sector, which was down 0.14% .SXDP.
British rival GSK's GSK.L shares are up 4.1% this year and Swiss drugmaker Roche ROG.S is up 11% this year, compared with the STOXX 600 Index gains of 7%.
AstraZeneca expects both 2024 revenue and core earnings per share to increase by a mid-teens percentage at constant currency rates, it said. It had previously expected revenue and profit to increase by a low double-digit to low-teens percentage.
The UK's most valuable company in terms of its market capitalisation of 189.4 billion pounds ($243.89 billion) has evolved significantly since CEO Pascal Soriot took over 12 years ago. New technologies such as antibody-drug conjugates are making up a rising proportion of its future cancer therapies.
The sales outlook reflects how the company has moved beyond the COVID vaccine, its best-selling product at the height of the pandemic in 2021, thanks to its roster of cancer therapies and a strong pipeline, including new treatments in other disease areas by the end of the decade.
"In the year to date we have continued to make encouraging progress with several disruptive technologies ... all of which have the potential to drive our growth beyond 2030," CEO Soriot said in a statement.
At its investor day in May, the company announced it aimed to grow revenue by about 75% to $80 billion by 2030, citing the expected launch of 20 new medicines and growth in its cancer, biopharmaceuticals and rare disease portfolio.
The company has been investing in building its pipeline and marketing new launches. In May, AstraZeneca said that a plant in Qingdao, China, will help it build a distinct local supply chain to serve the Chinese market, its second largest globally.
Operating expenses in the quarter were 14% higher at $6.74 billion.
Total revenue rose 17% on a constant-currency basis to $12.94 billion for the three months ended June, while core earnings came in at $1.98 per share, compared with analysts' average expectation of $12.6 billion and $1.98 per share, respectively, according to a company-compiled consensus.
AstraZeneca increased its interim dividend by 7 cents to $1.
($1 = 0.7766 pounds)
Reporting by Pushkala Aripaka in Bengaluru and Maggie Fick in London; Editing by Sonia Cheema and Elaine Hardcastle
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.
